Boston Medical Sciences Is Betting $37.6 Million on a Laxative-Free Colonoscopy

For many, the thought of a colonoscopy is not about the procedure itself, but the day before it. The rigorous, often unpleasant bowel preparation involving laxatives is a well-documented barrier to screening, one that Boston Medical Sciences believes it can engineer away. The Tokyo-based startup is developing a software system that applies deep learning to CT colonography images, digitally removing stool and residual material to create a cleansed, analyzable view of the colon without the patient ever taking a laxative [NEDO, October 2026]. It’s a bet on patient experience as a critical lever for public health, backed by a $37.6 million Series B round that signals investor confidence in its technical and regulatory path [PR TIMES, November 2026].

The Clinical Wedge

The company’s product, AIM4CRC, is classified as Software as a Medical Device (SaMD). Its core function is a two-step AI process: first, a ‘virtual bowel cleansing’ algorithm segments and subtracts fecal matter from a standard CT scan of the colon; second, a detection algorithm identifies and flags potential polyps for clinician review [FIRST CVC]. The clinical premise is straightforward. By eliminating the cathartic preparation, the system could make colorectal cancer screening more acceptable and accessible, potentially increasing participation rates in populations where the current standard is a significant deterrent [Maiko M. - Product Marketing Manager - Mizuho America, Inc., 2026]. For BMS, the patient’s comfort isn't a secondary feature, it's the primary intervention.

A Regulated Path Forward

Boston Medical Sciences is not operating in a regulatory vacuum. The company has reported that AIM4CRC has been accepted into the U.S. Food and Drug Administration’s Total Product Life Cycle Advisory Program (TAP Pilot), a move that provides early, interactive feedback from the agency during development [Boston Medical Sciences, 2026]. This is a notable signal for a startup based in Japan but eyeing the U.S. market. The recent Series B proceeds, which total approximately ¥5.55 billion, are earmarked for continued R&D, clinical work, and pursuing regulatory approvals in both Japan and the United States [PR TIMES, November 2026]. The investor syndicate, led by Japan Growth Capital Investment Corporation and including Nomura SPARX Investment, Global Brain Corporation, and repeat backer Beyond Next Ventures, brings both capital and presumably strategic connections for navigating these complex pathways [Nomura Holdings, November 2026].

The Founder's Prescription

The venture is led by Masaki Okamoto, the company’s founder and CEO. Public profiles link Okamoto to physician-researcher roles, suggesting the clinical origin of the idea is core to the company’s identity [PERPLEXITY SONAR PRO BRIEF]. While the solo-founder structure presents its own set of execution risks, the substantial Series B round indicates that investors are betting on Okamoto’s vision and the team he has built to deliver on a technically demanding problem. The company’s mission statement,“a world where no one dies from colorectal cancer”,frames the work not as another AI tool, but as a necessary re-imagination of a foundational screening modality [PERPLEXITY SONAR PRO BRIEF].

The Stakes for Screening

The ambition is significant, but the hurdles are familiar in medtech. The AI models must prove themselves not just in controlled trials but across diverse patient anatomies and imaging equipment. Regulatory clearance, while aided by the FDA TAP program, is never guaranteed and will require robust clinical validation data. Furthermore, adoption will require convincing gastroenterologists and radiologists to trust an AI-prepared view as much as a physically cleansed one, a shift in practice that goes beyond software accuracy.

• Technical validation. The AI’s performance in virtual cleansing and polyp detection must meet or exceed clinical benchmarks for sensitivity and specificity, a bar set by existing, preparation-required CT colonography and traditional colonoscopy.
• Market education. Even with regulatory approval, changing clinician behavior and patient referral patterns represents a separate, lengthy go-to-market challenge.
• Reimbursement landscape. Success ultimately depends on securing insurance reimbursement codes, a process that can lag far behind regulatory milestones.

The company’s focus is squarely on colorectal cancer screening, a critical public health initiative for adults over 45. The current standard of care for many remains the optical colonoscopy, an invasive procedure that requires sedation and the full bowel prep BMS seeks to avoid. CT colonography, while less invasive, still typically mandates the same rigorous preparation. For patients, the prospect of a screening test that foregoes the laxatives entirely could meaningfully lower the barrier to a life-saving check-up. For Boston Medical Sciences, proving that its AI can deliver that future reliably and safely is the multi-million dollar task now fully funded.

Sources

1. [NEDO, October 2026] Boston Medical Sciences, Inc. | https://www.nedo.go.jp/english/activities/startups/company10.html
2. [PR TIMES, November 2026] Boston Medical Sciences, Series B Round Raises ¥5.55 Billion in Equity | https://prtimes.jp/main/html/rd/p/000000012.000129637.html
3. [FIRST CVC] Boston Medical Sciences profile | https://b-ms.tech/
4. [Maiko M. - Product Marketing Manager - Mizuho America, Inc., 2026] LinkedIn post regarding AIM4CRC
5. [Boston Medical Sciences, 2026] Company announcement on FDA TAP Pilot Program
6. [Nomura Holdings, November 2026] Nomura SPARX Invests in Boston Medical Sciences | https://www.nomuraholdings.com/en/news/nr/nspi20261113a.html
7. [PERPLEXITY SONAR PRO BRIEF] Web-grounded research brief on Boston Medical Sciences
8. [Tracxn, February 2025] Boston Medical Sciences Series A funding details
9. [BRIDGE, February 2025] Boston Medical Sciences Raises 930 Million Yen in Series A | https://thebridge.jp/en/2025/02/boston-medical-sciences-raises-930-million-yen-in-series-a-funding